Travere Therapeutics (TVTX) Stock Forecast, Price Target & Predictions
TVTX Stock Forecast
Travere Therapeutics stock forecast is as follows: an average price target of $21.38 (represents a 18.12% upside from TVTX’s last price of $18.10) and a rating consensus of 'Buy', based on 15 wall street analysts offering a 1-year stock forecast.
TVTX Price Target
The average price target for Travere Therapeutics (TVTX) is $21.38 based on 1-year price targets from 15 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $12.00. This represents a potential 18.12% upside from TVTX's last price of $18.10.
TVTX Analyst Ratings
According to 15 Wall Street analysts, Travere Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for TVTX stock is 0 'Strong Buy' (0.00%), 12 'Buy' (80.00%), 3 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Travere Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 21, 2024 | Mohit Bansal | Wells Fargo | $27.00 | $17.87 | 51.09% | 49.17% |
| Oct 10, 2024 | Liisa Bayko | Evercore ISI | $30.00 | $18.07 | 66.02% | 65.75% |
| Oct 09, 2024 | Jason Zemansky | Bank of America Securities | $20.00 | $15.21 | 31.49% | 10.50% |
| Oct 01, 2024 | Carter Gould | Barclays | $18.00 | $13.99 | 28.66% | -0.55% |
| Sep 27, 2024 | Vamil Divan | Guggenheim | $23.00 | $15.04 | 52.93% | 27.07% |
| Sep 27, 2024 | Ed Arce | H.C. Wainwright | $18.00 | $15.04 | 19.68% | -0.55% |
| Sep 27, 2024 | Greg Harrison | Bank of America Securities | $18.00 | $14.01 | 28.48% | -0.55% |
| Sep 10, 2024 | Ed Nash | Canaccord Genuity | $23.00 | $12.70 | 81.17% | 27.07% |
| Sep 09, 2024 | Vamil Divan | Guggenheim | $25.00 | $12.62 | 98.18% | 38.12% |
| Aug 28, 2024 | Nicole Gabreski | Piper Sandler | $12.00 | $8.96 | 33.93% | -33.70% |
The latest Travere Therapeutics stock forecast, released on Oct 21, 2024 by Mohit Bansal from Wells Fargo, set a price target of $27.00, which represents a 51.09% increase from the stock price at the time of the forecast ($17.87), and a 49.17% increase from TVTX last price ($18.10).
Travere Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 3 | 10 | 13 |
| Avg Price Target | $25.67 | $21.40 | $20.85 |
| Last Closing Price | $18.10 | $18.10 | $18.10 |
| Upside/Downside | 41.82% | 18.23% | 15.19% |
In the current month, the average price target of Travere Therapeutics stock is $25.67, according to 3 Wall Street analysts offering twelve months forecast. The average price target represents a 41.82% increase as opposed to Travere Therapeutics's last price of $18.10. This month's average price target is up 19.95% compared to last quarter, and up 23.12% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 29, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Oct 21, 2024 | Wells Fargo | Sector Outperform | Sector Outperform | Hold |
| Oct 21, 2024 | Wells Fargo | Buy | Overweight | Upgrade |
| Oct 16, 2024 | Wedbush | Sector Outperform | Sector Outperform | Hold |
| Oct 16, 2024 | Scotiabank | - | Outperform | Initialise |
| Oct 10, 2024 | Evercore ISI | Outperform | Outperform | Hold |
| Oct 09, 2024 | Wedbush | Outperform | Outperform | Hold |
| Oct 01, 2024 | Barclays | Overweight | Overweight | Hold |
| Sep 27, 2024 | Leerink Partners | - | Market Perform | Downgrade |
| Sep 27, 2024 | Stephens | Overweight | Overweight | Hold |
Travere Therapeutics's last stock rating was published by Cowen & Co. on Oct 29, 2024. The company gave TVTX a "Buy" rating, the same as its previous rate.
Travere Therapeutics Financial Forecast
Travere Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $37.09M | $59.70M | $56.99M | $55.87M | $53.50M | $54.17M | $48.49M | $57.25M | $68.22M | $54.62M | $47.41M | $50.98M | $51.14M | $48.43M | $47.77M | $46.69M | $44.37M | $44.71M | $39.57M |
| Avg Forecast | $113.38M | $93.57M | $87.05M | $71.65M | $69.84M | $60.87M | $50.40M | $43.46M | $41.69M | $57.33M | $53.56M | $50.61M | $53.01M | $54.12M | $49.63M | $52.19M | $57.80M | $60.93M | $50.33M | $50.09M | $51.66M | $47.84M | $47.59M | $43.43M | $46.02M | $45.29M | $43.01M | $41.41M |
| High Forecast | $149.46M | $123.34M | $114.75M | $103.49M | $78.62M | $60.95M | $50.40M | $43.46M | $44.27M | $131.96M | $70.60M | $66.71M | $69.88M | $54.12M | $49.63M | $52.19M | $57.80M | $60.93M | $50.33M | $50.09M | $51.66M | $47.84M | $47.59M | $43.43M | $46.02M | $45.29M | $43.01M | $41.41M |
| Low Forecast | $89.90M | $74.19M | $69.02M | $50.76M | $60.81M | $60.78M | $50.40M | $43.46M | $39.31M | $15.17M | $42.47M | $40.13M | $42.03M | $54.12M | $49.63M | $52.19M | $57.80M | $60.93M | $50.33M | $50.09M | $51.66M | $47.84M | $47.59M | $43.43M | $46.02M | $45.29M | $43.01M | $41.41M |
| # Analysts | 3 | 3 | 3 | 5 | 11 | 5 | 5 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.65% | 1.11% | 1.13% | 1.05% | 0.99% | 1.09% | 0.93% | 0.99% | 1.12% | 1.09% | 0.95% | 0.99% | 1.07% | 1.02% | 1.10% | 1.01% | 0.98% | 1.04% | 0.96% |
Travere Therapeutics's average Quarter revenue forecast for Dec 23 based on 8 analysts is $41.69M, with a low forecast of $39.31M, and a high forecast of $44.27M. TVTX's average Quarter revenue forecast represents a 12.39% increase compared to the company's last Quarter revenue of $37.09M (Sep 23).
Travere Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 5 | 11 | 5 | 5 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-89.24M | $-85.69M | $-67.01M | $-65.03M | $-54.86M | $-50.99M | $-49.65M | $-42.15M | $-8.96M | $-25.98M | $-33.57M | $-17.36M | $-6.24M | $-11.23M | $-7.63M | $-11.11M | $-12.09M | $-25.62M | $-20.14M |
| Avg Forecast | $-75.93M | $-62.66M | $-58.30M | $-47.98M | $-46.77M | $-40.76M | $-33.75M | $-51.39M | $-27.92M | $-38.40M | $-35.87M | $-46.72M | $-34.03M | $-36.24M | $-33.24M | $-42.47M | $-38.71M | $-40.81M | $-33.71M | $-21.40M | $-34.60M | $-32.04M | $-31.87M | $-29.08M | $-30.82M | $-30.33M | $-28.80M | $-27.73M |
| High Forecast | $-60.20M | $-49.68M | $-46.22M | $-34.00M | $-40.72M | $-40.71M | $-33.75M | $-41.11M | $-26.32M | $-10.16M | $-28.44M | $-37.38M | $-27.22M | $-36.24M | $-33.24M | $-33.98M | $-38.71M | $-40.81M | $-33.71M | $-17.12M | $-34.60M | $-32.04M | $-31.87M | $-29.08M | $-30.82M | $-30.33M | $-28.80M | $-27.73M |
| Low Forecast | $-100.09M | $-82.60M | $-76.85M | $-69.30M | $-52.65M | $-40.82M | $-33.75M | $-61.67M | $-29.65M | $-88.37M | $-47.28M | $-56.06M | $-40.83M | $-36.24M | $-33.24M | $-50.97M | $-38.71M | $-40.81M | $-33.71M | $-25.68M | $-34.60M | $-32.04M | $-31.87M | $-29.08M | $-30.82M | $-30.33M | $-28.80M | $-27.73M |
| Surprise % | - | - | - | - | - | - | - | - | - | 2.32% | 2.39% | 1.43% | 1.91% | 1.51% | 1.53% | 1.17% | 1.09% | 0.22% | 0.77% | 1.57% | 0.50% | 0.19% | 0.35% | 0.26% | 0.36% | 0.40% | 0.89% | 0.73% |
undefined analysts predict TVTX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Travere Therapeutics's previous annual EBITDA (undefined) of $NaN.
Travere Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 5 | 11 | 5 | 5 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | $150.74M | $-85.63M | $-86.33M | $-65.82M | $-69.66M | $-67.03M | $-75.97M | $-51.57M | $-35.64M | $-39.01M | $-53.87M | $-121.62M | $-22.55M | $-26.07M | $808.00K | $-30.26M | $-36.49M | $-38.70M | $-40.98M |
| Avg Forecast | $5.76M | $-15.71M | $-21.16M | $-34.85M | $-48.69M | $-52.04M | $-61.52M | $-59.48M | $-90.04M | $-82.79M | $-84.67M | $-54.07M | $-43.38M | $-73.45M | $-72.76M | $-49.16M | $-57.02M | $-43.53M | $-52.96M | $-27.35M | $-33.33M | $-39.97M | $-35.65M | $-43.56M | $-45.61M | $-58.79M | $-38.86M | $-35.46M |
| High Forecast | $8.14M | $-11.48M | $-15.46M | $-9.06M | $-35.99M | $-38.03M | $-44.96M | $-47.58M | $-60.26M | $2.77B | $-61.87M | $-43.26M | $-34.71M | $-73.45M | $-72.76M | $-39.33M | $-57.02M | $-43.53M | $-52.96M | $-21.88M | $-33.33M | $-39.97M | $-35.65M | $-43.56M | $-45.61M | $-58.79M | $-38.86M | $-35.46M |
| Low Forecast | $4.21M | $-22.21M | $-29.91M | $-54.36M | $-62.80M | $-73.57M | $-86.97M | $-71.38M | $-109.89M | $-2.24B | $-119.69M | $-64.89M | $-52.06M | $-73.45M | $-72.76M | $-58.99M | $-57.02M | $-43.53M | $-52.96M | $-32.82M | $-33.33M | $-39.97M | $-35.65M | $-43.56M | $-45.61M | $-58.79M | $-38.86M | $-35.46M |
| Surprise % | - | - | - | - | - | - | - | - | - | -1.82% | 1.01% | 1.60% | 1.52% | 0.95% | 0.92% | 1.55% | 0.90% | 0.82% | 0.74% | 1.97% | 3.65% | 0.56% | 0.73% | -0.02% | 0.66% | 0.62% | 1.00% | 1.16% |
Travere Therapeutics's average Quarter net income forecast for Dec 23 is $-90.04M, with a range of $-109.89M to $-60.26M. TVTX's average Quarter net income forecast represents a -159.73% decrease compared to the company's last Quarter net income of $150.74M (Sep 23).
Travere Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 5 | 11 | 5 | 5 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | $67.80M | $74.04M | $72.25M | $62.92M | $57.52M | $52.98M | $46.79M | $42.08M | $36.06M | $34.97M | $36.78M | $35.74M | $31.95M | $34.97M | $33.14M | $27.53M | $29.78M | $38.97M | $32.67M |
| Avg Forecast | $106.28M | $87.71M | $81.59M | $67.16M | $65.47M | $57.05M | $47.24M | $36.63M | $39.08M | $53.74M | $50.20M | $33.30M | $35.39M | $50.73M | $46.52M | $30.27M | $54.18M | $57.11M | $47.18M | $18.67M | $48.42M | $44.84M | $44.61M | $40.70M | $43.14M | $42.45M | $40.31M | $38.81M |
| High Forecast | $140.09M | $115.61M | $107.56M | $97.00M | $73.69M | $57.13M | $47.24M | $43.96M | $41.49M | $123.69M | $66.18M | $39.96M | $42.47M | $50.73M | $46.52M | $36.33M | $54.18M | $57.11M | $47.18M | $22.41M | $48.42M | $44.84M | $44.61M | $40.70M | $43.14M | $42.45M | $40.31M | $38.81M |
| Low Forecast | $84.26M | $69.54M | $64.69M | $47.58M | $57.00M | $56.97M | $47.24M | $29.31M | $36.84M | $14.22M | $39.80M | $26.64M | $28.31M | $50.73M | $46.52M | $24.22M | $54.18M | $57.11M | $47.18M | $14.94M | $48.42M | $44.84M | $44.61M | $40.70M | $43.14M | $42.45M | $40.31M | $38.81M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.26% | 1.47% | 2.17% | 1.78% | 1.13% | 1.14% | 1.55% | 0.78% | 0.63% | 0.74% | 1.97% | 0.74% | 0.71% | 0.78% | 0.81% | 0.64% | 0.70% | 0.97% | 0.84% |
Travere Therapeutics's average Quarter SG&A projection for Dec 23 is $39.08M, based on 8 Wall Street analysts, with a range of $36.84M to $41.49M. The forecast indicates a -42.36% fall compared to TVTX last annual SG&A of $67.80M (Sep 23).
Travere Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 5 | 11 | 5 | 5 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | $1.98 | $-0.00 | $-1.27 | $-1.03 | $-1.09 | $-1.05 | $-1.20 | $-0.84 | $-0.59 | $-0.64 | $-0.96 | $-2.37 | $-0.44 | $-0.58 | $0.02 | $-0.70 | $-0.85 | $-0.92 | $-0.99 |
| Avg Forecast | $0.07 | $-0.20 | $-0.27 | $-0.45 | $-0.63 | $-0.67 | $-0.79 | $-0.96 | $-1.16 | $-1.06 | $-1.09 | $-1.20 | $-1.13 | $-0.95 | $-0.94 | $-0.87 | $-0.74 | $-0.56 | $-0.68 | $-0.52 | $-0.43 | $-0.52 | $-0.46 | $-0.56 | $-0.59 | $-0.76 | $-0.50 | $-0.46 |
| High Forecast | $0.10 | $-0.15 | $-0.20 | $-0.12 | $-0.46 | $-0.49 | $-0.58 | $-0.70 | $-0.77 | $35.55 | $-0.80 | $-0.88 | $-0.83 | $-0.95 | $-0.94 | $-0.87 | $-0.74 | $-0.56 | $-0.68 | $-0.52 | $-0.43 | $-0.52 | $-0.46 | $-0.56 | $-0.59 | $-0.76 | $-0.50 | $-0.46 |
| Low Forecast | $0.05 | $-0.29 | $-0.38 | $-0.70 | $-0.81 | $-0.95 | $-1.12 | $-1.36 | $-1.41 | $-28.74 | $-1.54 | $-1.70 | $-1.60 | $-0.95 | $-0.94 | $-0.87 | $-0.74 | $-0.56 | $-0.68 | $-0.52 | $-0.43 | $-0.52 | $-0.46 | $-0.56 | $-0.59 | $-0.76 | $-0.50 | $-0.46 |
| Surprise % | - | - | - | - | - | - | - | - | - | -1.86% | 0.00% | 1.06% | 0.91% | 1.15% | 1.12% | 1.38% | 1.14% | 1.05% | 0.94% | 1.84% | 5.51% | 0.85% | 1.26% | -0.04% | 1.19% | 1.12% | 1.83% | 2.16% |
According to 8 Wall Street analysts, Travere Therapeutics's projected average Quarter EPS for Dec 23 is $-1.16, with a low estimate of $-1.41 and a high estimate of $-0.77. This represents a -158.47% decrease compared to TVTX previous annual EPS of $1.98 (Sep 23).
Travere Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $2.15 | $33.86 | 1474.88% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| APLS | Apellis Pharmaceuticals | $28.56 | $76.13 | 166.56% | Buy |
| ANAB | AnaptysBio | $19.94 | $52.33 | 162.44% | Buy |
| STOK | Stoke Therapeutics | $13.10 | $30.60 | 133.59% | Buy |
| GPCR | Structure Therapeutics | $39.74 | $92.40 | 132.51% | Buy |
| LEGN | Legend Biotech | $43.61 | $82.62 | 89.45% | Buy |
| KROS | Keros Therapeutics | $59.95 | $102.00 | 70.14% | Buy |
| CYTK | Cytokinetics | $51.48 | $83.23 | 61.67% | Buy |
| IDYA | IDEAYA Biosciences | $30.00 | $48.36 | 61.20% | Buy |
| COGT | Cogent Biosciences | $11.87 | $18.83 | 58.64% | Buy |
| MGTX | MeiraGTx | $5.96 | $9.00 | 51.01% | Buy |
| AKRO | Akero Therapeutics | $32.05 | $46.00 | 43.53% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| RNA | Avidity Biosciences | $44.82 | $54.50 | 21.60% | Buy |
| NUVL | Nuvalent | $89.53 | $107.83 | 20.44% | Buy |
| TVTX | Travere Therapeutics | $18.10 | $21.38 | 18.12% | Buy |
| PCVX | Vaxcyte | $106.49 | $124.14 | 16.57% | Buy |
| PTGX | Protagonist Therapeutics | $46.76 | $50.00 | 6.93% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $55.87 | $58.57 | 4.83% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
TVTX Forecast FAQ
Is Travere Therapeutics a good buy?
Yes, according to 15 Wall Street analysts, Travere Therapeutics (TVTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 12 'Buy' recommendations, accounting for 80.00% of TVTX's total ratings.
What is TVTX's price target?
Travere Therapeutics (TVTX) average price target is $21.38 with a range of $12 to $30, implying a 18.12% from its last price of $18.1. The data is based on 15 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Travere Therapeutics stock go up soon?
According to Wall Street analysts' prediction for TVTX stock, the company can go up by 18.12% (from the last price of $18.1 to the average price target of $21.38), up by 65.75% based on the highest stock price target, and down by -33.70% based on the lowest stock price target.
Can Travere Therapeutics stock reach $30?
TVTX's average twelve months analyst stock price target of $21.38 does not support the claim that Travere Therapeutics can reach $30 in the near future.
What is Travere Therapeutics's current price target trend?
3 Wall Street analysts forecast a $25.67 price target for Travere Therapeutics (TVTX) this month, up 41.82% from its last price of $18.1. Compared to the last 3 and 12 months, the average price target increased by 18.23% and increased by 15.19%, respectively.
What are Travere Therapeutics's analysts' financial forecasts?
Travere Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $224.57M (high $233.43M, low $215.45M), average EBITDA is $-173M (high $-156M, low $-189M), average net income is $-222M (high $-167M, low $-295M), average SG&A $206.39M (high $222.02M, low $190.52M), and average EPS is $-3.045 (high $-2.23, low $-4.227). TVTX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $365.65M (high $491.04M, low $283.87M), average EBITDA is $-245M (high $-190M, low $-329M), average net income is $-65.957M (high $-27.862M, low $-102M), average SG&A $342.74M (high $460.26M, low $266.08M), and average EPS is $-0.848 (high $-0.358, low $-1.315).
Did the TVTX's actual financial results beat the analysts' financial forecasts?
Based on Travere Therapeutics's last annual report (Dec 2022), the company's revenue was $212.02M, beating the average analysts forecast of $208.96M by 1.47%. Apple's EBITDA was $-244M, beating the average prediction of $-146M by 67.36%. The company's net income was $-278M, beating the average estimation of $-239M by 16.64%. Apple's SG&A was $220.21M, beating the average forecast of $162.91M by 35.17%. Lastly, the company's EPS was $-4.37, beating the average prediction of $-3.891 by 12.32%. In terms of the last quarterly report (Sep 2023), Travere Therapeutics's revenue was $37.1M, missing the average analysts' forecast of $57.33M by -35.30%. The company's EBITDA was $-89.241M, beating the average prediction of $-38.396M by 132.42%. Travere Therapeutics's net income was $150.74M, missing the average estimation of $-82.791M by -282.07%. The company's SG&A was $67.8M, beating the average forecast of $53.74M by 26.16%. Lastly, the company's EPS was $1.98, missing the average prediction of $-1.064 by -286.01%